Today: 20 March 2026
Subscribe
Browse Category

NYSE:NVO 24 August 2025 - 4 November 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo Nordisk made an unsolicited $8.5 billion bid for Metsera, topping Pfizer’s earlier $7.3 billion deal. Metsera’s board called Novo’s offer “superior,” triggering a four-day window for Pfizer to respond. Metsera shares jumped over 18% on the news, while Novo’s stock fell 3%. Pfizer criticized Novo’s move as “reckless,” warning it could suppress competition.
31 October 2025
····
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk shares closed at $54.78 on Oct. 21, down nearly 50% in 2025 and wiping out about $70 billion in market value. The Novo Nordisk Foundation forced a board overhaul, with chair Helge Lund and six directors to be replaced. Novo announced deals to buy Akero for up to $5.2 billion and license Omeros’ OMS906 for up to $2.1 billion. U.S. price pressure and Eli Lilly’s competition have weighed on investor sentiment.
22 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros shares soared about 146% on Oct. 15, 2025, closing near $10.11 after Novo Nordisk agreed to license its drug zaltenibart for up to $2.1 billion. Omeros will receive $340 million upfront, with the deal expected to close in Q4. The company will now focus on its lead drug narsoplimab, which is under FDA and EMA review. Analyst targets for Omeros stock range from $9 to $36.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

European stocks hit three-week lows Thursday, then rebounded Friday as the STOXX 600 fell 0.7% before rising 0.3%. U.S. President Trump’s new tariffs on drugs and trucks triggered a 2% drop in major pharma and truck stocks. The Bank of England warned on persistent UK inflation, while the ECB and Swiss National Bank held rates steady. Germany’s consumer confidence improved; Spain’s GDP beat forecasts.
26 September 2025
········
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

NASA confirmed its 6,000th exoplanet discovery, while astronomers observed a black hole speeding away at over 50 km/s after a merger. A weight-loss pill version of Ozempic led to 16% body weight loss in trials, and a quick EEG test detected early Alzheimer’s. Engineers nearly doubled refrigeration efficiency with nano-thin films. AI designed viruses that killed drug-resistant E. coli in lab tests.
21 September 2025
···
Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

A 2024 trial found liraglutide reduced brain shrinkage by about 50% and slowed cognitive decline in mild Alzheimer’s, but missed its main goal. Larger semaglutide trials are underway, with results expected in late 2025. A major exenatide trial in Parkinson’s showed no benefit, while ALS studies remain inconclusive. Pharmaceutical companies are expanding research into GLP-1 drugs for neurodegenerative diseases.
10 September 2025
·
Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Chemists unveiled a “4-in-1” obesity drug targeting four hormones for bariatric surgery-level weight loss, aiming to avoid Ozempic’s side effects. German neuroscientists traced early Alzheimer’s smell loss to immune cells destroying neural links. A study warns the Atlantic’s ocean circulation could collapse after 2100 under high emissions. The Great Atlantic Sargassum Belt hit a record 37.5 million tons, fouling beaches from Africa to the Gulf of Mexico.
2 September 2025
·
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

The FDA cleared Rocket Pharma to resume its gene therapy trial for Danon disease after a patient death halted the study in May; the trial will restart with a lower dose and without the immune-suppressing drug linked to the fatal complication. Rocket shares jumped over 30% after the decision. Early data showed Dynavax’s shingles vaccine matched GSK’s Shingrix in immune response but caused fewer side effects, sending Dynavax shares up 7%.
24 August 2025
···
1 … 4 5 6 7

Stock Market Today

  • US Stocks Fall Amid Middle East Crisis and Rising Yields; Dow Drops 239 Points
    March 20, 2026, 3:48 PM EDT. U.S. stocks dropped sharply on March 20, 2026, driven by escalating Middle East conflict and a surge in Treasury yields. The Dow Jones fell 239 points (-0.52%) to 45,751. The S&P 500 slid 0.84% and the Nasdaq declined 1.28%, pressured by tech sell-offs including a 26% crash in Super Micro Computer after federal charges. Energy stocks showed resilience as crude oil prices neared $97.50 a barrel, stoking inflation fears. The 10-year Treasury yield jumped to 4.38%, raising rate hike odds. Gold and silver made tentative gains, while Bitcoin steadied near $70,000. Investors are poised for volatility pending geopolitical developments and economic data, with higher oil prices and inflation concerns clouding the outlook.
Go toTop